TORONTO, Sept. 29, 2026 (GLOBE NEWSWIRE) — GLOBEX MINING ENTERPRISES INC. (GMX – Toronto Stock Exchange, G1MN – Frankfurt, Stuttgart, Berlin, Munich, Tradegate, Lang & Schwarz, LS Exchange, TTMzero, Düsseldorf and Quotrix Düsseldorf Stock Exchanges and GLBXF – OTCQX International in the US) is pleased to inform shareholders that Albright Metals Limited have announced a Mineral Resource Estimate for the Vail Road Gold Deposit in New Brunswick (under Australian JORC 2012 Code) under option from Globex. The update incorporates assays, geology, rock density and structural data from additional drilling by Albright Metals in late 2025.

The new Global Mineral Resource Estimate for the Vail Road Gold Deposit (Devils Pike) is reported as 188,000 t grading 9.0 g/t Au for 54,200 contained gold ounces at a 2.0 g/t Au cut-off grade, including an initial Indicated Category portion of 33,500 t grading 20.9 g/t Au for 22,500 contained gold ounces.

The JORC 2012 code Mineral Reserve Estimate will be used as the bases for a Scoping Study. Also, noteworthy is that high-grade extensions have been identified for additional drilling. This new JORC Code updates a 2011 Canadian NI 43-101 resource estimate. This 2026 JORC 2012 Mineral Resource incorporates geology logging and assay results for 24 additional drill holes for 4,349.5 m of core drilling completed by Rockport in 2011 and 2012 and 15 additional diamond core holes for 1,022.5 m by Albright Metals in 2025. The additional drilling helped to refine the resource and the density applied to it. In addition, the new resource uses a lower cut-off grade of 2 g/t Au, versus 5 g/t Au in the 2011 NI 43-101 resource.

Table 1 – Vail Road Gold Deposit 2026 Mineral Resource by Resource Category and Zone

Category Zone Kilotonne
(kt)
Au g/t Au ozs
(000s)
Cu ppm

Indicated

Main 11.1 31.1 11.1 4,010
Middle 10.4 19.5 6.6 3,338
Parallel 11.9 12.7 4.9 2,067
Subtotal 33.5 20.9 22.5 3,107

Inferred

Main 42.2 4.0 5.4 1,881
Middle 6.8 10.0 2.2 1,797
Parallel 105.6 7.1 24.1 1,395
Subtotal 154.6 6.4 31.7 1,545
GLOBAL TOTAL 188.0 9.0 54.2 1,823
           

Note: Mineral Resource reported at 2 g/t Au cut-off grade; Numbers may not add up due to rounding; Tonnages are dry metric tonnes; Kilotonne = 1,000 tonnes; 10,000 ppm = 1%

The new resource estimate now contains a portion in the Indicated Mineral Resource category based upon an improved understanding of the structural controls of the veining and gold mineralization.

Figure 1 – Vail Road Gold Deposit Mineral Resource and Drill Collar Plan

Vail Road Gold Deposit Mineral Resource and Drill Collar Plan

Figure 2 – Vail Road Gold Deposit Section A – A’

Vail Road Gold Deposit Section A – A’

Shareholders may access the 51-page Albright press release which provides extensive data upon geology, assaying methodology, drilling techniques and hole spacings, sampling methods, etc. by clicking here.

Jack Stoch, P.Geo., Executive Chairman and CEO of Globex, in his capacity as a Qualified Person (Q.P.) under Ni 43-101, prepared the information that forms the basis of this written disclosure.

We Seek Safe Harbour.   Foreign Private Issuer 12g3 – 2(b)
  CUSIP Number 379900 50 9
LEI 529900XYUKGG3LF9PY95
For further information, contact:
 
Jack Stoch, P.Geo., Acc.Dir.
Executive Chairman & CEO
Globex Mining Enterprises Inc.
120 Carlton Street, Unit 219
Toronto, Ontario, Canada M5A 4K2
Tel.: 819.797.5242
Fax: 819.797.1470
info@globexmining.com
www.globexmining.com
   

Caution Regarding Forward-Looking Statements

Certain statements included in this press release may constitute “forward-looking statements” within the meaning of applicable Canadian securities laws. Except as may be required by such laws, Globex Mining Enterprises Inc. (“Globex”) does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements, by their very nature, are subject to numerous risks and uncertainties. As a result, actual results could differ materially from Globex’s expectations expressed in or implied by such forward-looking statements. No assurance can be given that any events anticipated by the forward-looking statements will materialize, or if any of them do, what benefits Globex will derive therefrom. Numerous risk factors which may cause actual results to differ materially from expectations expressed in or implied by the forward-looking statements are discussed in Globex’s annual information form for the 2025 fiscal year filed with the Canadian securities regulatory authorities, available on SEDAR+ at www.sedarplus.ca and on Globex’s website at www.globexmining.com. Globex cautions readers that such risks are not the only ones that could impact it. Additional risks and uncertainties not currently known to Globex or that Globex currently deems to be immaterial may have a material adverse effect on Globex’s business, financial condition, and results of operations. Given these risks and uncertainties, Globex cautions investors and others against placing undue reliance on such forward-looking statements as a prediction of future results or for any other purpose. This press release does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein have not been and will not be registered under the Securities Act of 1933, as amended (the “1933 Act”), or with any securities regulatory authority of any state or other jurisdiction in the United States, and may not be offered or sold, directly or indirectly, within the United States or to, or for the account or benefit of, U.S. persons (as such term is defined in Regulation S under the 1933 Act), except pursuant to an exemption from or in a transaction not subject to the registration requirements of the 1933 Act.

CALGARY, Alberta, Sept. 29, 2026 (GLOBE NEWSWIRE) — Precision Drilling Corporation (Precision) intends to release its 2026 third quarter results after the market closes on Tuesday, October 27, 2026, and has scheduled a conference call to begin at 11:00 a.m. MT (1:00 p.m. ET) on the next day, Wednesday, October 28, 2026.

To participate in the conference call please register at the URL link below. Once registered, you will receive a dial-in number and a unique PIN, which will allow you to ask questions.

https://register-conf.media-server.com/register/BI27fd4ada3a914d5282393d8c375188ec

The call will also be webcast and can be accessed through the link below. A replay of the webcast call will be available on Precision’s website until the following quarterly conference call is posted.

https://edge.media-server.com/mmc/p/x59h75bk

About Precision

Precision is a leading provider of safe and environmentally responsible High Performance, High Value services to the energy industry, offering customers access to an extensive fleet of Super Series drilling rigs. Precision has commercialized an industry-leading digital technology portfolio known as Alpha™ that utilizes advanced automation software and analytics to generate efficient, predictable, and repeatable results for energy customers. Our drilling services are enhanced by our EverGreen™ suite of environmental solutions, which bolsters our commitment to reducing the environmental impact of our operations. Additionally, Precision offers well service rigs, camps and rental equipment all backed by a comprehensive mix of technical support services and skilled, experienced personnel.

Precision is headquartered in Calgary, Alberta, Canada and is listed on the Toronto Stock Exchange under the trading symbol “PD” and on the New York Stock Exchange under the trading symbol “PDS”.

Additional Information

For more information about Precision, please visit our website at www.precisiondrilling.com or contact:

Lavonne Zdunich, CPA, CA
Vice President, Investor Relations
403.716.4500

800, 525 – 8th Avenue S.W.
Calgary, Alberta, Canada T2P 1G1
Website: www.precisiondrilling.com

Regular quarterly dividend increased 5.5% year-over-year, to $0.24 per share

Board declares additional $0.01 per share special dividend, bringing total third-quarter payment to $0.25 per share

ARCHBOLD, Ohio, Sept. 29, 2026 (GLOBE NEWSWIRE) — The Board of Directors of Farmers & Merchants Bancorp, Inc., (Nasdaq: FMAO) the holding company of F&M Bank, with total assets of $3.50 billion at June 30, 2026, today announced that it has approved the Company’s quarterly cash dividend of $0.24 per share. In addition, the Board approved a one-time special cash dividend of $0.01 per share, bringing the total third quarter dividend payment to $0.25 per share in recognition of America’s 250th anniversary.   Together, the third-quarter and special dividend of $0.25 per share will be paid on October 20, 2026, to shareholders of record as of October 9, 2026.

Compared to the prior dividend payment, the $0.24 per share cash dividend reflects a $0.01 per share, or 4.3% increase in the quarterly dividend and a $0.04 per share increase in the Company’s annual dividend. For over 50 years, F&M has paid a quarterly dividend and has increased its annual dividend for 32 consecutive years.

Lars B. Eller, President and Chief Executive Officer stated, “Our 32nd consecutive annual dividend increase reflects F&M’s consistent financial performance, strong capital position and long-term commitment to delivering value to our shareholders. Over the past 10 years, F&M’s annualized dividend has increased by approximately 109%, underscoring the consistency and durability of our commitment. Returning capital through a growing dividend remains an important component of our disciplined capital allocation strategy, and we are proud to maintain one of the longest records of consecutive annual dividend increases among publicly traded banks.”

Mr. Eller continued, “As we commemorate America’s 250th anniversary, our Board is also pleased to declare a special $0.01 per share dividend, bringing our total third-quarter payment to $0.25 per share. F&M’s history spans nearly 130 years, and we are proud to recognize this important national milestone while sharing our continued success with our shareholders.”

About F&M Bank:
F&M Bank is a local independent community bank that has been serving its communities since 1897. F&M Bank provides commercial banking, retail banking and other financial services. Our locations are in Butler, Champaign, Fulton, Defiance, Hancock, Henry, Lucas, Shelby, Williams, and Wood counties in Ohio. In Northeast Indiana, we have offices located in Adams, Allen, DeKalb, Jay, Steuben and Wells counties. The Michigan footprint includes Oakland County, and we have Loan Production Offices in Muncie, Indiana, and Perrysburg and Bryan, Ohio.

Safe Harbor Statement
Farmers & Merchants Bancorp, Inc. (“F&M”) wishes to take advantage of the Safe Harbor provisions included in the Private Securities Litigation Reform Act of 1995. Statements by F&M, including management’s expectations and comments, may not be based on historical facts and are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are typically identified by words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “seek,” “estimate,” “project,” “target,” “goal,” “will,” “would,” and similar expressions. Actual results could vary materially depending on risks and uncertainties inherent in general and local banking conditions, competitive factors specific to markets in which F&M and its subsidiaries operate, future interest rate levels, legislative and regulatory decisions, capital market conditions, deposit flows and pricing, liquidity and access to wholesale funding, interest rate and asset-liability management, credit quality (including commercial real estate exposures), collateral values, inflation and macroeconomic conditions, changes in laws and regulations (including capital and liquidity requirements and the implementation of “Basel III Endgame”), FDIC assessments, stress testing and supervisory expectations, cybersecurity and third-party/vendor risks, competition and technological change, geopolitical events, severe weather and natural disasters, agricultural sector conditions, the accuracy of CECL estimates and other accounting judgments, capital and dividend restrictions, and other risks described in F&M’s filings with the SEC. F&M undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. For more details, please refer to F&M’s SEC filing, including its most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q. Such filings can be viewed at the SEC’s website, www.sec.gov or through F&M’s website www.fm.bank.

Company Contact: Investor and Media Contact:
Lars B. Eller
President and Chief Executive Officer
Farmers & Merchants Bancorp, Inc.
(419) 446-2501
leller@fm.bank
Andrew M. Berger
Managing Director
SM Berger & Company, Inc.
(216) 464-6400
andrew@smberger.com
   

Sales of all remaining properties have now been completed

Board approves declaration of $1.74 per share additional liquidating distribution

Delisting from NYSE anticipated to occur in early November 2026

BETHESDA, Md., Sept. 29, 2026 (GLOBE NEWSWIRE) — Elme Communities (“Elme” or the “Company”) (NYSE: ELME) today provided an update on its ongoing liquidation activities, including the completion of the sales of all of its remaining properties, as well as the declaration of an additional liquidating distribution and updates on the anticipated timing of delisting from the New York Stock Exchange (the “NYSE”), establishment of a liquidating trust for purposes of completing the wind-down process and dissolution of the Company.

Update on Property Sale Activities

As previously disclosed, the Company completed the sale of Riverside Apartments on September 14, 2026 and used a portion of the proceeds from that sale to repay in full all remaining indebtedness, liabilities and other obligations under the Company’s $520 million term loan entered into on November 12, 2025 (the “Term Loan”), which has been terminated.

On September 28, 2026, the Company completed the sale of its final two remaining properties, The Kenmore and 3801 Connecticut Avenue. After satisfaction of prorations and closing costs, the Company received aggregate net proceeds of approximately $103.2 million for these sales. After completing these sales, the Company has now completed the disposition of all of its remaining properties.

Declaration of Additional Liquidating Distribution

Elme also announced today that its Board of Trustees (the “Board”) has approved an additional special liquidating distribution of $1.74 (the “Special Dividend”) per common share of beneficial interest, par value $0.01 per share (“Common Share”). The Special Dividend will be paid on October 22, 2026 to shareholders of record at the close of business on October 9, 2026. This brings the aggregate cash liquidating distributions to $16.41 per Common Share, inclusive of the $14.67 per share paid to shareholders in January 2026. The Special Dividend is being made in accordance with the Company’s voluntary Plan of Sale and Liquidation previously approved by its shareholders.

NYSE Due Bills

Because the payment of the Special Dividend represents more than 25% of the price of a Common Share, the NYSE has advised the Company that the Common Shares will trade with “due bills” representing an assignment of the right to receive the Special Dividend from the record date of October 9, 2026 through the closing of trading on the NYSE on October 22, 2026, which is the payment date and last day of trading before the October 23, 2026 ex-dividend date (this period of time from October 9, 2026 to October 22, 2026 representing the “Dividend Right Period”). Due bills obligate a seller of Common Shares to deliver the Special Dividend payable on such Common Shares to the buyer (the “Dividend Right”).

This means that persons who purchase Common Shares during the Dividend Right Period are entitled to receive the Special Dividend, and persons who sell Common Shares during the Dividend Right Period are not entitled to the Special Dividend. Accordingly, if an investor wishes to receive the Special Dividend, the investor will need to hold their Common Shares through and including the payment date of October 22, 2026. The record date of October 9, 2026 will be used as the date for establishing the due bill tracking of the Dividend Right to the holder of Common Shares.

Due bill obligations are customarily settled between the brokers representing the buyers and the sellers of shares. The Company has no obligation for either the amount of the due bill or the processing of the due bill. Buyers and sellers of the Common Shares should consult their brokers before trading to be sure they understand the effect of NYSE’s due bill procedures.

Anticipated Timing of NYSE Delisting, Establishment of a Liquidating Trust and Company Dissolution

On September 29, 2026, the Company, in accordance with the authority granted by the Board pursuant to the Plan of Sale and Liquidation, provided notice to the NYSE of its intention to voluntarily delist its Common Shares from the NYSE. The Company anticipates filing a Form 25, or Notification of Removal from Listing, with the Securities and Exchange Commission (“SEC”) and the NYSE relating to the delisting of the Common Shares on October 26, 2026. The Company anticipates the last day of trading on the NYSE to be November 5, 2026 and that the Company’s share transfer books will be closed as of 4:00 p.m. (Eastern Time) on such date. After payment of the Special Dividend and delisting from the NYSE, the Company will continue the process of winding down as further described below.

In accordance with the Plan of Sale and Liquidation, following delisting from the NYSE as described above, the Company intends to terminate its existence by voluntary dissolution, effective November 6, 2026. Prior to such dissolution, the Company intends to transfer all of its remaining assets and liabilities to a Maryland liquidating trust (the “Liquidating Trust”). The purpose of the Liquidating Trust will be to liquidate the assets of the Liquidating Trust and distribute the residual proceeds of such assets to the holders of the beneficial interests of the Liquidating Trust (the “Beneficial Interests”). All of the Beneficial Interests will be held by the shareholders of the Company, with each shareholder of the Company being deemed automatically to have received and hold a percentage of Beneficial Interests in the Liquidating Trust corresponding to such shareholder’s percentage ownership in the Company as of the close of business on the last day of trading of the Common Shares on the NYSE. Shareholders of the Company will not be required to take any action to receive Beneficial Interests in the Liquidating Trust. Following the transfer of the Company’s assets and liabilities to the Liquidating Trust, subject to certain exceptions related to transfer by will, intestate succession or operation of law, Beneficial Interests in the Liquidating Trust will not be transferable, nor will holders of Beneficial Interests have authority or power to sell or in any other manner dispose of their Beneficial Interests. Beneficial Interests will not trade on the NYSE or any other exchange. Simultaneously, all of the outstanding Common Shares and certificates representing Common Shares will be automatically cancelled and will thereafter no longer be deemed outstanding. The rights of holders of Beneficial Interests in the Liquidating Trust will not be represented by any form of certificate or other instrument. Based on guidance previously provided by the SEC in similar circumstances, assuming the Company terminates its existence as described above, the Company anticipates that the Liquidating Trust will be required to file only annual reports on Form 10-K (using the SEC file number of the Company) containing unaudited financial statements, as well as current reports on Form 8-K (also filed using the SEC file number of the Company). 

After giving effect to the Special Dividend, the Company’s remaining assets (which consist primarily of the net cash proceeds from property sales) are expected to be used to complete the wind-down process and satisfy all remaining liabilities, including Company liabilities, costs and expenses to be satisfied prior to dissolution of the Company and other known liabilities, net costs or expenses expected to be satisfied by the Liquidating Trust during the wind-down process, all of which are currently estimated to be approximately $23.3 million. In addition, the Company currently expects that approximately $9.5 million of additional cash reserves will be transferred to the Liquidating Trust to cover liabilities, costs or expenses that exceed estimated amounts, as well as any unknown or additional liabilities, costs or expenses that may arise prior to completion of the wind-down process. Any amounts remaining in the Liquidating Trust after satisfaction of all remaining liabilities (including any additional liabilities, costs and expenses that may arise during the wind-down process) are expected to be distributed to the holders of Beneficial Interests upon completion of the wind-down process and in connection with termination of the Liquidating Trust. The decision regarding the amount to be retained and transferred to the Liquidating Trust involved a number of judgments and assumptions and no assurance can be made as to when, or whether, the Liquidating Trust will be able to make any additional liquidating distribution(s) to holders of Beneficial Interests or the timing of any such distribution(s). The Company expects FTI Consulting, Inc. to be retained to provide services in connection with completing the wind-down process, including the services of a liquidating trustee. The actual amount and timing of payment of any additional liquidating distribution(s) would be made by the trustee of the Liquidating Trust in its sole discretion.

U.S. Federal Income Tax Consequences

Information regarding the expected U.S. federal income tax consequences of the Special Dividend, any additional liquidating distributions, as well as the Plan of Sale and Liquidation of the Company, are summarized in the Company’s definitive proxy statement, filed with the SEC on September 24, 2025, for the special meeting of shareholders held on October 30, 2025, which is available free of charge through the website maintained by the SEC at http://www.sec.gov or Elme’s website at www.elmecommunities.com. However, the tax treatment described may vary depending on each shareholder’s particular situation.

About Elme Communities

Elme Communities is a Maryland real estate investment trust which currently trades on the New York Stock Exchange under the ticker symbol ELME.

Contact:
Investor Relations
202-774-3200 

Forward-Looking and Cautionary Statements

Certain statements in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and involve risks and uncertainties. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. In some cases, you can identify forward looking statements by the use of forward-looking terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” or “potential” or the negative of these words and phrases or similar words or phrases which are predictions of or indicate future events or trends and which do not relate solely to historical matters. Such statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of Elme to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Additional factors which may cause the actual results, performance, or achievements of Elme to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements include, but are not limited to: Elme’s timeline for delisting its securities from the NYSE; Elme’s ability to transfer its remaining assets and liabilities to the Liquidating Trust and terminate its existence by voluntary dissolution on the terms and timeline anticipated; changes in the amount and timing of the additional liquidating distributions, including from the Liquidating Trust, as a result of known liabilities or contingent costs or expenses that may be higher than anticipated liabilities, costs or expenses, or unknown, liabilities, costs or expenses that arise in the future which Elme cannot reasonably estimate at this time; the possibility, mechanics and timing of converting to a liquidating trust or other liquidating entity; the ability of the Board to terminate the Plan of Sale and Liquidation; potential difficulties in running the Company with a small number of employees until the transfer of the Company’s remaining assets and liabilities to the Liquidating Trust; the outcome of legal proceedings that may be instituted against Elme, its trustees and others, including those related to the sale of 19 multifamily assets to an affiliate of Cortland Partners, LLC, and other completed sales and the Plan of Sale and Liquidation; risks relating to the market value of the Common Shares; risks associated with third party contracts containing consent and/or other provisions that may be triggered by the Plan of Sale and Liquidation; whether or not the sale of one or more of Elme’s properties may be considered a prohibited transaction under the Internal Revenue Code of 1986, as amended; Elme’s ability to maintain its status as a real estate investment trust for U.S. federal income tax purposes; the occurrence of any event, change or other circumstances that could give rise to the termination of the Plan of Sale and Liquidation; general economic and market developments and conditions; and volatility and uncertainty in the financial markets.

The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties that affect Elme’s businesses in the “Risk Factors” section of Elme’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other documents filed by Elme from time to time with the SEC. Copies of the documents filed by Elme with the SEC are available free of charge through the website maintained by the SEC at http://www.sec.gov, and are also available, free of charge, on Elme’s website at www.elmecommunities.com. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. While forward-looking statements reflect Elme’s good faith beliefs, they are not guarantees of future performance. Elme undertakes no obligation to update its forward-looking statements or risk factors to reflect new information, future events, or otherwise.

JOHNS CREEK, Ga., Sept. 29, 2026 (GLOBE NEWSWIRE) — Saia, Inc. (Nasdaq: SAIA) announced that it will release its quarterly financial results before the market opens on Thursday, October 29th. Saia management will host a conference call to discuss the results later that morning at 10:00 a.m. Eastern Time.

To participate in the call, please dial 1-833-890-5317 and request to join the Saia, Inc. call. Callers should dial in five to ten minutes in advance of the conference call. This call will be webcast live via the company website at https://www.saia.com/about-us/investor-relations/financial-releases. A replay of the call will be offered two hours after the completion of the call through November 29, 2026 at 11:59 P.M. Eastern Time. The replay will be available by dialing 1-855-669-9658 referencing conference ID #3959947.

Saia, Inc. (Nasdaq: SAIA) offers customers a wide range of less-than-truckload, brokered truckload, expedited transportation and other logistics services. With headquarters in Georgia, Saia LTL Freight operates 218 terminals with national service. For more information on Saia, Inc. visit the Investor Relations section at https://www.saia.com/about-us/investor-relations.

CONTACT:      Saia, Inc.
    Matthew Batteh
    Executive Vice President and Chief Financial Officer
    Investors@Saia.com 

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) — Verizon Communications Inc. (NYSE, Nasdaq: VZ) today announced the election of Charles Phillips, Co-Founder & Managing Partner of Recognize Partners LP (“Recognize”), to the Verizon Board of Directors, effective immediately.

“Charles is an accomplished leader with distinctive experience in technology, financial and regulatory environments,” said Dan Schulman, Verizon CEO. “We look forward to his perspective and contributions on the board to help us innovate faster, delight our customers and drive sustainable, long-term value for our shareholders.”

With the addition of Mr. Phillips, the Verizon board consists of 10 directors with a broad mix of perspectives and expertise.

Mr. Phillips has served as Co-Founder and Managing Partner of Recognize, a private equity firm focused on investing in technology services businesses, since January 2020. Prior to Recognize, Mr. Phillips was the Executive Chairman of Infor, Inc., an enterprise software application provider, from 2019 to 2020 and Chief Executive Officer from 2010 to 2020. He served as President of Oracle Corporation from 2003 to 2010 and as a Managing Director in Morgan Stanley’s Technology Group from 1996 to 2003. Mr. Phillips also served as Captain in the U.S. Marine Corps.

Mr. Phillips holds a B.S. in Computer Science from the U.S. Air Force Academy, an M.B.A. from Hampton University and a J.D. from New York Law School. He also serves on the boards of directors of American Express, Bloomberg LP, Compass Inc., the Apollo Theater, and the Council of Foreign Relations.

This announcement was originally published by Verizon. Read the original press release.

Verizon Communications Inc. (NYSE, Nasdaq: VZ) powers and empowers how its millions of customers live, work and play, delivering on their demand for mobility, reliable network connectivity and security. Headquartered in New York City, serving countries worldwide and nearly all of the Fortune 500, Verizon generated revenues of $138.2 billion in 2025. Verizon’s world-class team never stops innovating to meet customers where they are today and equip them for the needs of tomorrow. For more, visit verizon.com or find a retail location at verizon.com/stores

Media contact: 
Katie Magnotta
201-602-9235
katie.magnotta@verizon.com

MINNEAPOLIS, Sept. 29, 2026 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today the schedule of scientific presentations featuring Barostim at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026. The meeting will be held Oct. 9-12, 2026, in Phoenix.

Barostim will be featured across eight events at HFSA, including late-breaking clinical data, a rapid-fire session, posters and podium sessions. BENEFIT-HF, the landmark clinical trial initiated earlier this year evaluating Barostim in an expanded population, will also be included in the clinical trial ePoster hub.

New REBALANCE Registry and Real-World HFmrEF Evidence
In a late-breaking session, Dr. Dmitry Yaranov will present new analyses from the REBALANCE Registry, the largest real-world study of Barostim-treated patients to date, evaluating the safety and benefits of Barostim in commercial use.

In a separate rapid-fire session, Dr. Javed Butler will present Baroreflex Activation Therapy in HFmrEF: First Real-World Evidence of Reduced Hospitalization Burden.

In addition to the REBALANCE and HFmrEF presentations, Barostim will be featured in numerous scientific sessions and activities throughout the HFSA Annual Scientific Meeting 2026.

Barostim on the HFSA Annual Scientific Meeting 2026 Agenda

Friday, Oct. 9:

  • Devices in Heart Failure Meeting, Discussion Forum – Making a Choice CCM or Barostim (Dr. Elizabeth Volz and Dr. Omar Cantu Martinez)
  • Devices in Heart Failure Meeting, Trial Tinder: Choose my Trial! – BENEFIT-HF (Dr. Farooq Sheikh)
  • ePoster, Barostim Enabled Neurohormonal Intervention for Improving Treatment of Heart Failure (BENEFIT-HF) (Dr. William Abraham)

Saturday, Oct. 10:

  • Poster, Interaction Testing Between Barostim Neo Device and Assure Wearable Cardiac Defibrillator (Dr. Rhea Verma)

Sunday, Oct. 11:

  • Sunday Plenary Session, The REBALANCE Registry: Real World Outcomes Following Baroreflex Activation Therapy (Dr. Dmitry Yaranov)
  • Rapid Fire Session 2, Baroreflex Activation Therapy in HFmrEF: First Real-World Evidence of Reduced Hospitalization Burden (Dr. Javed Butler)
  • Poster, Optimizing Management of Heart Failure with Reduced Ejection Fraction Using Baroreflex Activation Therapy: A Path to Diuretic Independence (Dr. Shreya Srivastava)

Monday, Oct. 12:

  • Game of Thrones House of Devices: Restoring the Realm’s Failing Hearts, House Lannister: Barostim Takes Up Arms (Dr. Sarah Chuzi)

CVRx Sponsored Programs
CVRx will host two symposia sharing insights on Barostim’s role in the heart failure care continuum and its integration into clinical practice.

On Friday, Oct. 9 from 7:00–8:30 a.m., Device-Based Neurohormonal Intervention: The Role of Barostim in Heart Failure Care will explore the clinical evidence supporting Barostim, patient selection, integration into guideline-directed care and practical considerations for implementation.

On Sunday, Oct. 11 from 1:00–2:00 p.m., Successful Barostim Program Development: A Critical Component of the Heart Failure Care Continuum will address multidisciplinary collaboration, patient identification, referral pathways, workflow integration and best practices for developing and sustaining a successful Barostim program.

“We are excited by the scientific interest in Barostim at this year’s HFSA conference, with four separate data sets, five podium discussions and two symposia focused on practical elements for incorporating Barostim into clinical practice,” said Kevin Hykes, President and Chief Executive Officer of CVRx. “The data being presented provide important new scientific insights about Barostim across patient populations, clinical outcomes and real-world practice, contributing to a broader understanding of its role in the heart failure continuum.”

About CVRx, Inc.
CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure.

Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Investor Contact:
Mark Klausner or Mike Vallie
ICR Healthcare
443-213-0501
ir@cvrx.com

Media Contact:
Emily Meyers
CVRx, Inc.
763-416-2853
emeyers@cvrx.com

Tokyo, JAPAN and New York, NY, Sept. 29, 2026 (GLOBE NEWSWIRE) — Linkage Global Inc. (NASDAQ: UZX) (“Linkage Global” or the “Company”), a technology-driven enterprise focused on AI-enabled wellness infrastructure, today announced that the non-binding term sheet dated September 12, 2026 between the Company and Capital Finance Limited (“Capital Finance”), as amended by an addendum dated September 14, 2026 (collectively, the “LOI”), relating to a proposed strategic equity investment of up to US$20 million, was terminated effective September 28, 2026.

On September 28, 2026, the Company delivered, and Capital Finance acknowledged and agreed to, a written termination notice terminating the LOI with immediate effect. The parties will not proceed with the proposed transaction. No definitive securities purchase agreement was entered into, and no securities were issued or funds received in connection with the proposed transaction.

Except for provisions that expressly survive termination, the LOI ceased to have further force or effect on September 28, 2026. The termination does not affect any rights or remedies accrued before that date, and the confidentiality obligations under the LOI will remain in effect for three years following termination.

Linkage Global remains focused on its core business operations and will continue to evaluate strategic and financing opportunities that it believes may advance the interests of the Company and its shareholders.

About Linkage Global Inc.

Linkage Global Inc. (NASDAQ: UZX) is a technology-driven enterprise pioneering global AI-enabled wellness infrastructure. Through its proprietary Human Resonance OS, the Company integrates self-developed neural acoustic algorithms, a portfolio of original wellness audio copyrights, and next-generation smart wearables to deliver data-driven, proactive wellness solutions to B2B and B2C markets worldwide. Founded on March 24, 2022, Linkage Global is headquartered in Tokyo, Japan. For more information, visit: https://linkagecc.com

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, including, but not limited to, the Company’s plans, strategies and business development initiatives. There can be no assurance that any strategic initiative, partnership, offering launch, or other business plan described herein will be successfully executed or completed. This press release does not constitute guidance and should not be relied upon as indicative of future financial performance. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the U.S. Securities and Exchange Commission.

For investor and media inquiries, please contact:

Linkage Global Inc.
Investor Relations
Email: ir@linkagecc.com

Houston, TX, Sept. 29, 2026 (GLOBE NEWSWIRE) — CenterPoint Energy, Inc. (NYSE: CNP) has scheduled a conference call for Tuesday, October 27, 2026, at 7:00 a.m. Central time or 8:00 a.m. Eastern time, to discuss Third Quarter results. Earnings will be released on the same day before the market opens.

CenterPoint Energy will provide a live audio webcast of the conference call, which can be accessed at CenterPointEnergy.com. Click on “Events & Presentations” and the link, “CenterPoint Energy, Inc. Third Quarter 2026 Earnings Conference Call Webcast.” The webcast will be archived on the company’s website for at least one year.

CenterPoint Energy, Inc.

Third Quarter 2026 Earnings Conference Call

Tuesday, October 27, 2026

7:00 a.m. Central / 8:00 a.m. Eastern

About CenterPoint Energy

As the only investor owned electric and gas utility based in Texas, CenterPoint Energy, Inc. (NYSE: CNP) is an energy delivery company with electric transmission and distribution, power generation and natural gas distribution operations that serve more than 7 million metered customers in Indiana, Minnesota, Ohio and Texas. As of June 30, 2026, the company owned approximately $48.3 billion in assets. With approximately 8,800 employees, CenterPoint Energy and its predecessor companies have been in business for more than 150 years. For more information, visit CenterPointEnergy.com.

CONTACT: Ben Vallejo | (713) 207-5461 | Ben.vallejo@centerpointenergy.com

BOSTON, Sept. 29, 2026 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it has commenced a registered public offering (the “Offering”) of (i) shares of its common stock, or in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock, and (ii) accompanying common warrants to purchase shares of common stock. Each share of common stock and each pre-funded warrant will be sold together with a common warrant to purchase one share of common stock.

The common warrants will become exercisable only upon approval by the Company’s stockholders of an amendment to the Company’s certificate of incorporation to increase the number of authorized shares of common stock and the effectiveness of that amendment (the date of such effectiveness, the “Charter Amendment Effective Date”), and will expire upon the earlier of (i) the fifth anniversary of the Charter Amendment Effective Date and (ii) the 30th calendar day following the later (x) of the Charter Amendment Effective Date and (y) the Company’s public disclosure of overall survival data (the “OS Data Release Date”) from its ongoing Phase 1 monotherapy study of micvotabart pelidotin (MICVO) in second-line and beyond (2L+) recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), expected in the first half of 2027. All of the securities in the Offering are to be sold by Pyxis Oncology.

Leerink Partners, Guggenheim Securities and Wells Fargo Securities are acting as joint bookrunning managers for the proposed Offering. The proposed Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed or as to the actual size or terms of the Offering.

Pyxis Oncology intends to use the net proceeds from the Offering to advance its lead clinical program, MICVO, through key clinical milestones, including Headliner™, its planned Phase 3 trial in 2L+ R/M HNSCC, and for working capital and general corporate purposes.

The common stock, common warrants and pre-funded warrants are being offered pursuant to a registration statement on Form S-3 (File No. 333-291801), which was previously filed with and subsequently declared effective by the Securities and Exchange Commission (the “SEC”). The Offering will be made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A copy of the preliminary prospectus supplement relating to and describing the terms of the Offering will be filed with the SEC and will be available for free on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus may also be obtained, when available, from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at 1-800-808-7525 ext. 6105, or by email at syndicate@leerink.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; or from Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 90 South 7th Street, 5th Floor, Minneapolis, Minnesota 55402, at (800) 645-3751 (option #5) or email a request to WFScustomerservice@wellsfargo.com.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in the Offering, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Pyxis Oncology

Pyxis Oncology, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for difficult-to-treat cancers. The Company’s lead candidate, micvotabart pelidotin (MICVO), is a first-in-concept antibody-drug conjugate (ADC) that targets extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix (ECM). EDB+FN is selectively overexpressed in the tumor microenvironment of a wide range of solid tumors and largely absent from normal adult tissues. MICVO is designed to treat solid tumors through a three-pronged mechanism of action: direct cancer cell killing, bystander effect and immunogenic cell death. MICVO is currently being evaluated as monotherapy in a Phase 1 clinical study in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in a Phase 1/2 clinical study in patients with R/M HNSCC and other solid tumors. Pyxis Oncology is focused on advancing MICVO, with the goal of improving outcomes for patients living with R/M HNSCC and contributing to meaningful progress in cancer treatment.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Forward-Looking Statements

This press release contains forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this press release, including without limitation statements regarding the anticipated Offering, including its timing, size, terms and completion and the anticipated gross proceeds therefrom (including from any exercise of the common warrants); the Company’s ability to obtain stockholder approval of, and to effect, the amendment to its certificate of incorporation required for the common warrants to become exercisable, and the timing thereof; the timing of the OS Data Release Date, which will affect the period during which the common warrants may be exercised; the Company’s intended use of the net proceeds from the Offering; the Company’s plans to develop, manufacture and commercialize MICVO; the timing and progress of the Company’s ongoing clinical trials and the expected results thereof; the plans and objectives of management; and the future results of operations and financial position of the Company, are forward-looking statements. These statements are neither promises nor guarantees, but are statements that involve known and unknown risks, uncertainties and other important factors that are in some cases beyond the Company’s control that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: market and other conditions and the Company’s ability to complete the Offering on the anticipated terms, or at all; the Company’s ability to obtain the stockholder approval required for the common warrants to become exercisable; the timing and results of the overall survival analysis from the Company’s Phase 1 monotherapy study of MICVO; the risks inherent in drug research and development; the Company’s projected cash runway and potential needs for additional funding; the lengthy, expensive and uncertain process of clinical drug development, including potential delays in or failure to obtain regulatory approvals; the Company’s reliance on third parties and collaborators to conduct clinical trials, manufacture its product candidate, and develop and commercialize its product candidate; the Company’s ability to compete successfully against other drug candidates; and volatility in the price of the Company’s common stock. Accordingly, investors should not rely upon forward-looking statements as predictions of future events. Except as required by applicable law, the Company undertakes no obligation to update publicly or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Additionally, investors should read the risk factors in the section titled “Risk Factors” set forth in Part II, Item 1A of the Company’s Quarterly Report on Form 10-Q filed on August 13, 2026, in the preliminary prospectus supplement relating to the Offering, and in the Company’s other filings, each of which is on file with the Securities and Exchange Commission.

Pyxis Oncology Contact:
IR@pyxisoncology.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.